In this episode, experts explore the real-world challenges of treating patients with MASLD. From choosing which patients to start on therapy, to navigating drug interactions, and treatment duration. The panel unpacks how to decide when to initiate, continue, or stop treatment, and how to recognise treatment futility.

Moderator: Cyrielle Caussy

Boehringer Ingelheim Representative: Mazen Noureddin

Madrigal Representative: Maru Rinella

Novo Nordisk Representative: Philip Newsome

This EASL Studio is supported by Boehringer Ingelheim, Madrigal and Novo Nordisk.